144 related articles for article (PubMed ID: 21619949)
1. Therapeutic blockade of TNF in patients with SLE-promising or crazy?
Aringer M; Smolen JS
Autoimmun Rev; 2012 Mar; 11(5):321-5. PubMed ID: 21619949
[TBL] [Abstract][Full Text] [Related]
2. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Aringer M; Graninger WB; Steiner G; Smolen JS
Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
[TBL] [Abstract][Full Text] [Related]
4. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.
Aringer M; Steiner G; Graninger WB; Höfler E; Steiner CW; Smolen JS
Arthritis Rheum; 2007 Jan; 56(1):274-9. PubMed ID: 17195231
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of infliximab in active SLE: a pilot study.
Uppal SS; Hayat SJ; Raghupathy R
Lupus; 2009 Jul; 18(8):690-7. PubMed ID: 19502264
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus.
Aringer M; Smolen JS
Expert Opin Drug Saf; 2008 Jul; 7(4):411-9. PubMed ID: 18613805
[TBL] [Abstract][Full Text] [Related]
7. The role of tumor necrosis factor-alpha in systemic lupus erythematosus.
Aringer M; Smolen JS
Arthritis Res Ther; 2008; 10(1):202. PubMed ID: 18226185
[TBL] [Abstract][Full Text] [Related]
8. SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus.
Aringer M; Smolen JS
Arthritis Res Ther; 2003; 5(4):172-7. PubMed ID: 12823847
[TBL] [Abstract][Full Text] [Related]
9. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
[TBL] [Abstract][Full Text] [Related]
10. Lessons for lupus from tumour necrosis factor blockade.
De Bandt M
Lupus; 2006; 15(11):762-7. PubMed ID: 17153848
[TBL] [Abstract][Full Text] [Related]
11. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
12. The role of Tumor Necrosis Factor-alpha (TNF-α) in the pathogenesis of systemic lupus erythematosus.
Postal M; Appenzeller S
Cytokine; 2011 Dec; 56(3):537-43. PubMed ID: 21907587
[TBL] [Abstract][Full Text] [Related]
13. Anti-TNF-induced lupus.
Williams EL; Gadola S; Edwards CJ
Rheumatology (Oxford); 2009 Jul; 48(7):716-20. PubMed ID: 19416947
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.
Jimenez-Boj E; Kedersha N; Tohidast-Akrad M; Karlhofer FM; Stummvoll G; Zimmermann C; Ulrich W; Guiducci S; Hoefler E; Aringer M; Schett G; Matucci-Cerinic M; Smolen JS; Steiner G
Arthritis Rheum; 2008 May; 58(5):1226-36. PubMed ID: 18438838
[TBL] [Abstract][Full Text] [Related]
15. [Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis].
Haake H; Köneke J; Amann K; vom Dahl J; Janssen U
Med Klin (Munich); 2007 Oct; 102(10):852-7. PubMed ID: 17928969
[TBL] [Abstract][Full Text] [Related]
16. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis.
Enghard P; Langnickel D; Riemekasten G
Scand J Rheumatol; 2006; 35(3):209-16. PubMed ID: 16766368
[TBL] [Abstract][Full Text] [Related]
17. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases.
Braun A; Sis J; Max R; Mueller K; Fiehn C; Zeier M; Andrassy K
Scand J Rheumatol; 2007; 36(4):291-8. PubMed ID: 17763207
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies to tumor necrosis factor in patients with rheumatoid arthritis and systemic lupus erythematosus.
Rosenau BJ; Schur PH
J Rheumatol; 2009 Apr; 36(4):753-6. PubMed ID: 19273453
[TBL] [Abstract][Full Text] [Related]
19. Induction of systemic lupus erythematosus-like syndrome in syngeneic mice by immunization with activated lymphocyte-derived DNA.
Qiao B; Wu J; Chu YW; Wang Y; Wang DP; Wu HS; Xiong SD
Rheumatology (Oxford); 2005 Sep; 44(9):1108-14. PubMed ID: 15840592
[TBL] [Abstract][Full Text] [Related]
20. Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers.
Ferraccioli G; Gremese E
Autoimmun Rev; 2004 Jun; 3(4):261-6. PubMed ID: 15246021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
